Core Insights - Immutep Limited announced positive results from the EFTISARC-NEO Phase II trial, demonstrating significant efficacy of eftilagimod alfa (efti) in combination with radiotherapy and KEYTRUDA® for resectable soft tissue sarcoma (STS) [1][5] - The trial met its primary endpoint, achieving a median tumor hyalinization/fibrosis of 51.5%, significantly exceeding the prespecified target of 35% [1][5] - The results indicate a potential for improved overall survival and recurrence-free survival in STS patients, addressing a substantial unmet medical need in this area [2][5] Company Overview - Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 [7] - The company aims to provide innovative treatment options and maximize shareholder value through its diversified product portfolio [7] Clinical Trial Details - The EFTISARC-NEO Phase II trial was investigator-initiated and involved a diverse population of STS subtypes, showcasing a robust safety profile with minimal severe toxicity [1][2] - The study was primarily funded by a grant from the Polish government through the Polish Medical Research Agency program [2] Eftilagimod Alfa (Efti) Mechanism - Efti is an MHC Class II agonist that activates antigen-presenting cells, stimulating both adaptive and innate immune responses to combat cancer [4][6] - The therapy is under evaluation for various solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma, with favorable safety allowing for multiple combination therapies [6]